GlycoMimetics (NASDAQ:GLYC) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.01), Morningstar.com reports.
GlycoMimetics stock traded down $0.12 during mid-day trading on Friday, reaching $9.13. The company had a trading volume of 722,562 shares, compared to its average volume of 700,790. GlycoMimetics has a fifty-two week low of $8.29 and a fifty-two week high of $17.07. The company has a debt-to-equity ratio of 0.02, a quick ratio of 23.88 and a current ratio of 23.88. The firm has a market cap of $399.43 million, a P/E ratio of -7.74 and a beta of 2.45. The company has a fifty day moving average of $11.16.
GLYC has been the topic of several analyst reports. Zacks Investment Research upgraded shares of GlycoMimetics from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research report on Thursday, July 4th. HC Wainwright reiterated a “buy” rating and set a $23.00 price target on shares of GlycoMimetics in a research report on Friday, April 12th. BidaskClub lowered shares of GlycoMimetics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 24th. Cowen restated a “buy” rating on shares of GlycoMimetics in a research report on Friday, May 3rd. Finally, Piper Jaffray Companies initiated coverage on shares of GlycoMimetics in a research report on Friday, April 12th. They issued an “overweight” rating and a $20.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $23.00.
GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML.
Recommended Story: Preferred Stock
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.